NEW YORK, June 19, 2023 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Reata Pharmaceuticals, Inc. (NASDAQ:RETA), DLocal Ltd. (NASDAQ:DLO), Comerica Incorporated (NYSE:CMA), and Advance Auto Parts, Inc. (NYSE:AAP). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
Reata Pharmaceuticals, Inc. (NASDAQ:RETA)
On May 10, 2023, Reata issued a press release announcing its financial results for the first quarter of 2023. Among other items, Reata announced its decision to discontinue studies for its kidney disease candidate bardoxolone, which the Company had previously advanced as one of its lead assets in partnership with Blackstone Life Sciences and Kyoma Kirin.
On this news, Reata’s stock price fell $14.99 per share or 14.23%, to close at $90.38 per share on May 10, 2023.
For more information on the Reata investigation go to: https://bespc.com/cases/RETA
DLocal Ltd. (NASDAQ:DLO)
On November 16, 2022, Muddy Waters Capital LLC (“Muddy Waters”) published a research report concluding that DLocal “is likely a fraud.” Muddy Waters alleges that DLocal has repeated disclosures about its Total Processing Volume and accounts receivable “that flatly contradict one another” and that there is “a contradictory discrepancy between two key subsidiaries’ accounts payable and accounts …
